Clinical Edge Journal Scan

Entheseal fibrocartilage abnormalities: A potential imaging biomarker of PsA


 

Key clinical point: The entheseal fibrocartilage (EF) thickness assessed during power Doppler ultrasound evaluation was significantly different among patients with psoriatic arthritis (PsA) and control individuals and can be explored as an imaging biomarker for PsA.

Major finding: The median EF thickness was significantly greater in patients with PsA and athletes vs control individuals (0.035 and 0.036 vs 0.030 cm, respectively; P = .05 and P = .008, respectively), with the intra- and inter-reader reliability of the evaluation of EF thickness being excellent (intraclass correlation coefficient [ICC] 0.91) and good (ICC 0.80; both P < .001), respectively.

Study details: This cross-sectional study included patients with PsA (n = 30), athletes (n = 40), and control individuals (n = 20) who underwent power Doppler ultrasound evaluation during bilateral Achilles tendon insertions.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Perrotta FM et al. Ultrasonographic evaluation of entheseal fibrocartilage in patients with psoriatic arthritis, athletes and healthy controls: A comparison study. Diagnostics (Basel). 2023; 13(8):1446 (Apr 17). Doi: 10.3390/diagnostics13081446

Recommended Reading

Vitamin D deficiency associated with lowest retention rates of first bDMARD in PsA
Psoriatic Arthritis ICYMI
Age at disease onset influences disease characteristics in PsA
Psoriatic Arthritis ICYMI
Are patients with PsA more prone to cancer?
Psoriatic Arthritis ICYMI
Patients with PsA have lower vitamin D levels than general population, says meta-analysis
Psoriatic Arthritis ICYMI
Study identifies risk factors associated with PsA occurrence in patients with psoriasis
Psoriatic Arthritis ICYMI
Commentary: PsA development risks, and a new index, May 2023
Psoriatic Arthritis ICYMI
Secukinumab improves treatment outcomes and inhibits structural damage in PsA
Psoriatic Arthritis ICYMI
Enthesitis resolution similar with secukinumab and adalimumab in PsA
Psoriatic Arthritis ICYMI
Sonographic enthesitis associated with sonographic synovitis and tenosynovitis in PsA
Psoriatic Arthritis ICYMI
Upadacitinib safe and effective in PsA patients with axial involvement
Psoriatic Arthritis ICYMI